We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | 장 마감 후 (AMC) | $0.67 | — | — | $180.34M | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $0.51 | — | — | $170.53M | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $2.32 | — | — | $545.44M |
Consensus PT $23.33 · 6 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 14. | Wells Fargo | — | 투자의견 하향 | Overweight → Equal-Weight | — | Wells Fargo: Overweight → Equal-Weight |
| 2026. 05. 12. | Piper Sandler | — | 의견 유지 | Neutral → Neutral | — | Piper Sandler: Neutral |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $1.54 | — | — | $354.23M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Stored first · Google News · Yahoo Finance (English)
Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference - Corsicana Daily Sun
Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference Corsicana Daily Sun
Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference - Yahoo Finance
Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference Yahoo Finance
Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference
3 Stocks Under $50 with Open Questions
(AMPH) Risk Channels and Responsive Allocation - Stock Traders Daily
(AMPH) Risk Channels and Responsive Allocation Stock Traders Daily
Why Wells Fargo Lowered Amphastar Pharmaceuticals, Inc. (AMPH) Price Target to $19